Brought to you by 
Series C brings in $150mm for gene therapy start-up Orchard Therapeutics
14 Aug 2018
Executive Summary
Orchard Therapeutics Ltd. (autologous ex vivo gene therapies) brought in $150mm through an oversubscribed Series C round led by Deerfield Management, which was joined by new investors RA Capital Management, Venrock, Foresite Capital, Perceptive Advisors, Cormorant Asset Management, ArrowMark Partners, Sphera Global Healthcare, Medison Ventures, Driehaus Capital Management, Ghost Tree Capital Group, and US- based health care focused funds, along with returning backers Temasek, Baillie Gifford, RTW Investments, Cowen Healthcare Investments, and Agent Capital. Cowen served as the placement agent.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series C brings in $150mm for gene therapy start-up Orchard Therapeutics
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice